Syneos Health, Inc. Class A SYNH 深 滬
等待開盤 09-25 09:30:00 美东时间
42.98
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 42.98
- 總市值 446.99万
- 52周最高 52.23
- 市盈率 靜 16.69
- 換手率 0.00%
- 52周最低 22.894
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 104.18
- 量 比 0
- 振 幅 0.00%
- 歷史最低 22.894
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. announced its participation in three upcoming investor conferences in September 2026. CEO Bo Cumbo and CMO Gabriel Brooks will attend the 2026 Cantor Global Healthcare Conference on September 9 and the 2026 Citi Biopharma Back to School Conference on September 10. Cumbo will also participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Live webcasts and 90-day replays of each fireside cha...
09-02 12:00
Telix Appoints David Gill as Chair
David Gill appointed as Chair of Telix Pharmaceuticals Board, effective immediately. He joined Telix in May 2026 as a Non-Executive Director with the intention of becoming Chair. Dr. Mark Nelson, interim Chair, will continue as a Non-Executive Director. Gill brings over 35 years of experience in life sciences, financial leadership, and corporate strategy. Telix is a global radiopharmaceutical company advancing targeted theranostics for cancer tre...
08-31 22:21
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera Bio Ltd. has appointed Riccardo Camisasca, M.D., as its Chief Medical Officer. With over 30 years of experience in global pharmaceutical research and clinical development, Dr. Camisasca previously served as Global Head of Research & Development at Sumitomo Pharma Switzerland. His expertise will strengthen Entera’s clinical execution team and support the upcoming Phase 3 initiation of EB613, an oral anabolic treatment for osteoporosis. Dr. ...
08-18 12:00
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology appoints Nelson Azoulay as Chief Business Officer. With over 15 years of experience in corporate strategy and biopharma transactions, Azoulay will lead corporate development and advance MICVO, the company's lead ADC targeting EDB+FN in solid tumors. MICVO is in Phase 1/2 trials for recurrent/metastatic head and neck cancer and has received FDA Fast Track Designation. Azoulay's expertise in ADCs and strategic transactions is expecte...
05-07 20:05
Telix Appoints David Gill as Non-Executive Director
<p>Telix Pharmaceuticals Limited has appointed David Gill as a Non-Executive Director, effective May 11, 2026, with plans for him to become Chair in the future. Mr. Gill, a seasoned executive with over 35 years of experience in finance and leadership roles, brings expertise in capital markets, business scaling, and corporate strategy. Telix, a global biopharmaceutical company focused on radiopharmaceuticals, aims to strengthen its board as it con...
04-01 23:53
Syneos Health’s COGNIKET-MCI Trial: A Promising Step in Cognitive Health Research
Syneos Health (($SYNH)) announced an update on their ongoing clinical study. St...
2025-08-15 00:21
CytoDyn Phase 2 study of leronlimab cleared by FDA
CytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer. Patient enrollment for the study ...
2024-11-04 23:22
